-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

626A.O2.6 626. Aggressive Lymphomas: Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma

Symposia: Aggressive Lymphomas: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Adult, Lymphomas, Non-Hodgkin lymphoma, Epidemiology, Elderly, Assays, B Cell lymphoma, Clinical Research, Bioinformatics, Diseases, Aggressive lymphoma, Real-world evidence, Lymphoid Malignancies, Registries, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Sunday, December 8, 2024: 4:30 PM-6:00 PM
Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
Moderators:
Jennifer L. Crombie, MD, Dana Farber Cancer Institute and Pere Barba, MD, University Hospital Vall d'Hebron, Universitat Autònoma of Barcelona (UAB)
Disclosures:
Barba: Autolus: Consultancy; Kite-Gielead: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pfizer: Honoraria; Incyte: Honoraria; BMS: Honoraria.
4:30 PM

Sydney Dubois, MD, PhD1*, Fanny Cherblanc, PhD2*, Aurelien Belot, PhD3*, Lucie Oberic, MD4*, Herve Ghesquieres, MD, PhD5*, Corinne Haioun, MD, PhD6, Hervé Tilly7, Jean-Philippe Jais, MD, PhD8,9* and Fabrice Jardin, MD, PhD7*

1Department of Hematology and Inserm U1245, Centre Henri Becquerel, UNIROUEN, University of Normandie, Rouen, France, Rouen, France
2Lymphoma Academic Research Organisation, Lyon, France
3Biostatistics, LYSARC, Hôpital Lyon-Sud, Pierre-Bénite, FRA
4IUCT - Oncopole, Hematology Department, Toulouse, France
5Department of Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France
6Lymphoid Malignancies Department, Henri Mondor University Hospital, AP-HP, Créteil, France
7INSERM U1245, Cancer and Brain Genomics, Centre Henri Becquerel, University of Rouen, Rouen, France
8Hôpital Necker-Enfants Malades, PARIS, France
9Biostatistic Unit, Imagine Institut Inserm UMR 11 63, Paris, France

4:45 PM

Jelena Jelicic1*, Karen Juul-Jensen, MD, PhD2*, Zoran Bukumiric3*, Mikkel Runason Simonsen, MSc4,5*, Michael Roost Clausen, MD, PhD6*, Ahmed Al-Mashhadi, MD4,7*, Robert Schou Pedersen, MD, PhD8*, Christian Bjørn Poulsen, MD, PhD9,10*, Anne Ortved Gang9,11*, Peter Brown, MD, PhD9,11*, Tarec Christoffer Christoffer El-Galaly2,4,11,12 and Thomas Stauffer Larsen, MD, PhD2,13*

1Department of Hematology, Odense University Hospital, Odense, Denmark, Odense, AL, Denmark
2Department of Hematology, Odense University Hospital, Odense, Denmark, Odense, Denmark
3Institute for Medical Statistics and Informatics, University of Belgrade, Faculty of Medicine, Belgrade, Serbia
4Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
5Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark
6Dept. of Hematology, Vejle Hospital, Vejle, Denmark
7Dept. of Hematology, Aarhus University Hospital, Aarhus, Denmark
8Dept. of Hematology, Regionshospital Goedstrup, Goedstrup, Denmark
9Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
10Department of Hematology, Zealand University Hospital, Roskilde, Denmark
11Copenhagen University Hospital, Rigshospitalet, Denmark, Copenhagen, Denmark
12Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
13Department of Clinical Research, University of Southern Denmark, Odense, Denmark

5:00 PM

Jordan S Goldstein, MD, MSc1, Mark Roschewski, MD2, Won-Seog Kim3*, Sang Eun Yoon, MD4*, Seok Jin Kim, MD, PhD4, Jason R. Westin, MD5, Ryan C Lynch, MD6, Stefan K. Alig, MD7, Sandra Close, PhD8*, Jacob Chabon, PhD8*, Davide Rossi, MD, PhD9, Wyndham H. Wilson, MD, PhD10*, David Kurtz, MD, PhD11,12 and Ash A. Alizadeh, MD, PhD7

1Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Palo Alto, CA
2National Cancer Institute, Bethesda, MD
3Samsung Medical Center, Center for Hematologic Malignancy, Seoul, Korea, Republic of (South)
4Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Republic of (South)
5The University of Texas M D Anderson Cancer Center, Houston, TX
6Fred Hutchinson Cancer Center, Seattle, WA
7Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
8Foresight Diagnostics, Aurora, CO
9Institute of Oncology Research, Laboratory of Experimental Hematology, Bellinzona, Switzerland
10Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
11Department of Medicine (Oncology), Stanford University, Palo Alto, CA
12Foresight Diagnostics, Boulder, CO

5:15 PM

Edward R Scheffer Cliff, MBBS, MPH1, Guido D Pelaez, MD2, Fei Wan, PhD3*, Varun Iyengar, MD4, Jihao Zhou, MD, PhD5*, Kevin Chung, MD6, Nayef Abdel-Razeq, MD7*, Ajay Major, MD, MBA8, Jessica M Allen, MD8*, John Sharp, MD9, Narendranath Epperla, MD, MS9, Patrick Gould, MD, MBE10*, Hua-Jay J Cherng, MD11, Samin Houshyar, MD12*, Danielle S Wallace, MD12, Ryan C. Lynch, MD13, Avyakta Kallam, MBBS14, Matthew Mei, MD14, Reid W. Merryman, MD15, Michelle Fleyshman, MD16*, Joanna M. Rhodes, MD16, Adam Kidwell, MD17*, Timothy S. Fenske, MD17, Erin Mulvey, MD18, Marcus P. Watkins, PhD19*, Muhamad Alhaj Moustafa, M.D., M.S.7, Talal Hilal, MD20, Grzegorz S. Nowakowski, MD21, Yucai Wang, MD, PhD5, Pallawi Torka, MD4 and David A Russler-Germain, MD, PhD22

1Program on Regulation, Therapeutics and Law, Brigham and Women’s Hospital, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Medicine, Washington University School of Medicine, St. Louis, MO
3Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO
4Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5Division of Hematology, Mayo Clinic, Rochester, MN
6Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, AZ
7Division of Hematology, Mayo Clinic, Jacksonville, FL
8Division of Hematology, University of Colorado School of Medicine, Aurora, CO
9James Comprehensive Cancer Center, The Ohio State University, Columbus, OH
10Division of Hematology & Oncology, Columbia University Irving Medical Center, New York
11Division of Hematology & Oncology, Columbia University Irving Medical Center, Long Island City, NY
12Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
13Fred Hutchinson Cancer Center, University of Washington, Seattle, WA
14City of Hope Cancer Center, Duarte, CA
15Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
16Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
17Froedtert Hospital Cancer Center, Medical College of Wisconsin, Milwaukee, WI
18Weill Cornell Medicine, New York, NY
19Division of Oncology, Washington University School of Medicine, St. Louis, MO
20Division of Hematology and Oncology, Mayo Clinic Arizona, Phoenix, AZ
21Mayo Clinic, Rochester, MN
22Siteman Cancer Center, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

5:30 PM

Zhi Han Yeoh, MBBS, BMedSc, FRACP, FRCPA1,2,3, Ing Soo Tiong, FRACP, FRCPA, MPhil3,4, Mark R Dowling, MBBS, PhD5,6, Hamish W Scott, MD2*, Nicole O'Leary6*, Samantha van der Linde6*, Tamia Nguyen, BSc, MSc3,4*, Simon J Harrison, MBBS, PhD5,6, Ashish Bajel, MBBS, FRACP, FRCPA2,3, Andrew H Wei, MBBS, PhD, FRACP, FRCPA1,7,8 and Piers Blombery, MBBS4,9

1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
2Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
4Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
5Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia
6Centre of Excellence for Cellular Immunotherapy and Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
7Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
8The University of Melbourne, Melbourne, VIC, Australia
9Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia

5:45 PM

Sara Harrysson, MD1,2*, Sandra Eloranta, PhD3*, Stefanie Antonilli1*, Mikkel Runason Simonsen, MSc4*, Kristina Sonnevi, MD PhD5*, Peter de Nully Brown, MD, PhD6, Bjorn E Wahlin, MD, PhD7,8, P-O Andersson, MD, PhD9*, Judit Mészáros Joergensen, MD, PhD10*, Mats Jerkeman, MD, PhD11, Christian Bjørn Poulsen, MD, PhD12*, Gunilla Enblad, MD, PhD13*, Tarec Christoffer El-Galaly, MD, DMSc, Prof14,15,16 and Karin Ekstroem Smedby, MD7,17

1Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
2Hematology Department, Karolinska University Hospital, Stockholm, Sweden
3Department of Medicine Solna, Karolinska Institutet, Stockholm, SWE
4Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
5Karolinska University Hospital, Department of Haematology, Stockholm, Sweden
6Dept. of Hematology, Rigshospitalet, Copenhagen, Denmark
7Karolinska University Hospital, Stockholm, Sweden
8Hematology, Karolinska Institute, Solna, Sweden
9Sahlgrenska University Hospital, Gothenburg, Gothenburg, SWE
10Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
11Lund University Hospital, Lund, Sweden
12Department of Hematology, Zealand University Hospital, Roskilde, Denmark
13Department of Immunology, Genetics and Pathology, Cancer Immunotherapy Unit, Uppsala University, Uppsala, Sweden
14Department of Hematology, Odense University Hospital, Odense, Denmark
15Department of Hematology, Aalborg Hospital, Aalborg, Denmark
16Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
17Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

*signifies non-member of ASH